Federal Register / Vol. 88, No. 203 / Monday, October 23, 2023 / Notices 72793 

the Joint Board for enrollment purposes 

and acceptable to the other two actuarial 

organizations as part of their respective 

examination programs. 

2. Scope of Advisory Committee Duties 

The Advisory Committee plays an 

integral role in the examination program 

by assisting the Joint Board in offering 

examinations that enable examination 

candidates to demonstrate the 

knowledge necessary to qualify for 

enrollment. The Advisory Committee’s 

duties, which are strictly advisory, 

include (1) recommending topics for 

inclusion on the Joint Board 

examinations, (2) developing and 

reviewing examination questions, (3) 

recommending proposed examinations, 

(4) reviewing examination results and 

recommending passing scores, and (5) 

providing other recommendations and 

advice relative to the examinations, as 

requested by the Joint Board. 

3. Member Terms and Responsibilities 

Generally, members are appointed for 

a 2-year term. However, the member 

selected pursuant to this notice will be 

appointed for 12 months, beginning 

March 1, 2024. Members may seek 

reappointment for additional 

consecutive terms. 

Members are expected to attend 

approximately 4 meetings each calendar 

year and are reimbursed for travel 

expenses in accordance with applicable 

government regulations. For this 

appointment, the member is expected to 

attend approximately 4 meetings. 

Meetings may be held in-person or by 

teleconference. In general, members are 

expected to devote 125 to 175 hours, 

including meeting time, to the work of 

the Advisory Committee over the course 

of a year. 

4. Member Selection 

The Joint Board seeks to appoint an 

Advisory Committee that is fairly 

balanced in terms of points of view 

represented and functions to be 

performed. Every effort is made to 

ensure that most points of view extant 

in the enrolled actuary profession are 

represented on the Advisory Committee. 

To that end, the Joint Board seeks to 

appoint members from each of the main 

practice areas of the enrolled actuary 

profession, including small employer 

plans, large employer plans, and 

multiemployer plans. In addition, to 

ensure diversity of points of view, the 

Joint Board limits the number of 

members affiliated with any one 

actuarial organization or employed with 

any one firm. 

Membership normally will be limited 

to actuaries currently enrolled by the 

Joint Board. However, individuals 

having academic or other special 

qualifications of particular value for the 

Advisory Committee’s work also will be 

considered for membership. Federally 

registered lobbyists and individuals 

affiliated with Joint Board enrollment 

examination preparation courses are not 

eligible to serve on the Advisory 

Committee. 

5. Member Designation 

Advisory Committee members are 

appointed as Special Government 

Employees (SGEs). As such, members 

are subject to certain ethical standards 

applicable to SGEs. Upon appointment, 

each member will be required to 

provide written confirmation that he/ 

she does not have a financial interest in 

a Joint Board examination preparation 

course. In addition, each member will 

be required to attend annual ethics 

training. 

6. Application Requirements 

To receive consideration, an 

individual interested in serving on the 

Advisory Committee must submit (1) a 

signed, cover letter expressing interest 

in serving on the Advisory Committee 

and describing his/her professional 

qualifications, and (2) a resume and/or 

curriculum vitae. Applications must be 

submitted electronically to NHQJBEA@

irs.gov. The transmittal email should 

include APPLICATION FOR ADVISORY 

COMMITTEE in the subject line. 

Applications must be received by 

December 1, 2023. 

Dated: October 18, 2023. 

Thomas V. Curtin, Jr., 

Executive Director, Joint Board for the 

Enrollment of Actuaries. 

[FR Doc. 2023–23328 Filed 10–20–23; 8:45 am] 

BILLING CODE 4830–01–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–1284] 

Importer of Controlled Substances 

Application: Nexus Pharmaceuticals, 

Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Nexus Pharmaceuticals, Inc. 

has applied to be registered as an 

importer of basic class(es) of controlled 

substance(s). Refer to SUPPLEMENTARY

INFORMATION listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may submit 

electronic comments on or objections to 

the issuance of the proposed registration 

on or before November 22, 2023. Such 

persons may also file a written request 

for a hearing on the application on or 

before November 22, 2023. 

ADDRESSES: The Drug Enforcement 

Administration requires that all 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to 

https://www.regulations.gov and follow 

the online instructions at that site for 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. All 

requests for a hearing must be sent to: 

(1) Drug Enforcement Administration, 

Attn: Hearing Clerk/OALJ, 8701 

Morrissette Drive, Springfield, Virginia 

22152; and (2) Drug Enforcement 

Administration, Attn: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing should 

also be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on September 20, 2023, 

Nexus Pharmaceuticals, Inc., 10300 

128th Avenue, Pleasant Prairie, 

Wisconsin 53158–7336 applied to be 

registered as an importer of the 

following basic class(es) of controlled 

substance(s): 

Controlled substance Drug 

code Schedule 

Remifentanil .................. 9739 II 

The company plans to import the 

listed controlled substance for research 

and analytical testing purposes. No 

other activities for these drug codes are 

authorized for this registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonVerDate Sep<11>2014 17:24 Oct 20, 2023 Jkt 262001 PO 00000 Frm 00065 Fmt 4703 Sfmt 4703 E:\FR\FM\23OCN1.SGM 23OCN1

lotter on DSK11XQN23PROD with NOTICES1
72794 Federal Register / Vol. 88, No. 203 / Monday, October 23, 2023 / Notices 

approved finished dosage forms for 

commercial sale. 

Claude Redd, 

Acting Deputy Assistant Administrator. 

[FR Doc. 2023–23320 Filed 10–20–23; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF LABOR 

Occupational Safety and Health 

Administration 

[Docket No. OSHA–2010–0013] 

SolarPTL, LLC: Application for 

Expansion of Recognition 

AGENCY: Occupational Safety and Health 

Administration (OSHA), Labor. 

ACTION: Notice. 

SUMMARY: In this notice, OSHA 

announces the application of SolarPTL, 

LLC, for expansion of the scope of 

recognition as a Nationally Recognized 

Testing Laboratory (NRTL) and presents 

the agency’s preliminary finding to 

grant the application. 

DATES: Submit comments, information, 

and documents in response to this 

notice, or requests for an extension of 

time to make a submission, on or before 

November 7, 2023. 

ADDRESSES: Comments may be 

submitted as follows: 

Electronically: You may submit 

comments, including attachments, 

electronically at http://

www.regulations.gov, the Federal 

eRulemaking Portal. Follow the online 

instructions for submitting comments. 

Instructions: All submissions must 

include the agency’s name and the 

docket number for this rulemaking 

(Docket No. OSHA–2010–0013). All 

comments, including any personal 

information you provide, are placed in 

the public docket without change and 

may be made available online at https:// 

www.regulations.gov. Therefore, OSHA 

cautions commenters about submitting 

information they do not want made 

available to the public, or submitting 

materials that contain personal 

information (either about themselves or 

others), such as Social Security numbers 

and birthdates. 

Docket: To read or download 

comments or other material in the 

docket, go to http://

www.regulations.gov. Documents in the 

docket (including this Federal Register 

notice) are listed in the http://

www.regulations.gov index; however, 

some information (e.g., copyrighted 

material) is not publicly available to 

read or download through the website. 

All submissions, including copyrighted 

material, are available for inspection 

through the OSHA Docket Office. 

Contact the OSHA Docket Office at (202) 

693–2350 (TTY (877) 889–5627) for 

assistance in locating docket 

submissions. 

Extension of comment period: Submit 

requests for an extension of the 

comment period on or before November 

7, 2023 to the Office of Technical 

Programs and Coordination Activities, 

Directorate of Technical Support and 

Emergency Management, Occupational 

Safety and Health Administration, U.S. 

Department of Labor, 200 Constitution 

Avenue NW, Room N–3653, 

Washington, DC 20210, or by fax to 

(202) 693–1644. 

FOR FURTHER INFORMATION CONTACT: 

Information regarding this notice is 

available from the following sources: 

Press inquiries: Contact Mr. Frank 

Meilinger, Director, OSHA Office of 

Communications, U.S. Department of 

Labor, telephone: (202) 693–1999; 

email: meilinger.francis2@dol.gov. 

General and technical information: 

Contact Mr. Kevin Robinson, Director, 

Office of Technical Programs and 

Coordination Activities, Directorate of 

Technical Support and Emergency 

Management, Occupational Safety and 

Health Administration, U.S. Department 

of Labor, phone: (202) 693–2300 or 

email: robinson.kevin@dol.gov. 

SUPPLEMENTARY INFORMATION: 

I. Notice of the Application for 

Expansion 

OSHA is providing notice that 

SolarPTL, LLC. (PTL), is applying for an 

expansion of current recognition as a 

NRTL. PTL requests the addition of one 

test standard to the NRTL scope of 

recognition. 

OSHA recognition of a NRTL signifies 

that the organization meets the 

requirements specified in 29 CFR 

1910.7. Recognition is an 

acknowledgment that the organization 

can perform independent safety testing 

and certification of the specific products 

covered within the scope of recognition. 

Each NRTL’s scope of recognition 

includes (1) the type of products the 

NRTL may test, with each type specified 

by the applicable test standard and (2) 

the recognized site(s) that has/have the 

technical capability to perform the 

product-testing and productcertification activities for test standards 

within the NRTL’s scope. Recognition is 

not a delegation or grant of government 

authority; however, recognition enables 

employers to use products approved by 

the NRTL to meet OSHA standards that 

require product testing and certification. 

The agency processes applications by 

a NRTL for initial recognition, as well 

as for an expansion or renewal of 

recognition, following requirements in 

Appendix A to 29 CFR 1910.7. This 

appendix requires that the agency 

publish two notices in the Federal 

Register in processing an application. In 

the first notice, OSHA announces the 

application and provides the 

preliminary finding. In the second 

notice, the agency provides the final 

decision on the application. These 

notices set forth the NRTL’s scope of 

recognition or modifications of that 

scope. OSHA maintains an 

informational web page for each NRTL, 

including PTL, which details that 

NRTL’s scope of recognition. These 

pages are available from the OSHA 

website at http://www.osha.gov/dts/ 

otpca/nrtl/index.html. 

PTL currently has one facility (site) 

recognized by OSHA for product testing 

and certification, with the headquarters 

located at: SolarPTL, LLC, 1107 West 

Fairmont Drive, Tempe, Arizona 85282. 

A complete listing of PTL’s scope of 

recognition is available at https://

www.osha.gov/nationally-recognizedtesting-laboratory-program/solarptl. 

II. General Background on the 

Application 

PTL submitted an application, dated 

June 1, 2021 (OSHA–2010–0013–0005), 

to expand recognition as a NRTL to 

include one additional test standard. 

OSHA staff performed a detailed 

analysis of the application packet and 

reviewed other pertinent information. 

OSHA performed an on-site assessment 

related to this application on August 

16–17, 2022, where OSHA found 

nonconformances with the requirements 

of 29 CFR 1910. PTL addressed the 

nonconformances adequately and OSHA 

has no objection to the addition of this 

standard to the scope of recognition. 

Table 1 shows the test standard found 

in PTL’s application for expansion for 

testing and certification of products 

under the NRTL Program. 


lotter on DSK11XQN23PROD with NOTICES1